Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Pfizer Inc. (NYSE:PFE)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on November 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Pfizer Stock Down 1.9%

NYSE PFE opened at $25.05 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The business’s fifty day simple moving average is $25.09 and its 200-day simple moving average is $24.82. The firm has a market cap of $142.43 billion, a PE ratio of 14.56 and a beta of 0.46.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Citigroup began coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Morgan Stanley reduced their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Scotiabank assumed coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.06.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently bought and sold shares of the company. Keel Point LLC lifted its position in shares of Pfizer by 20.4% during the third quarter. Keel Point LLC now owns 18,255 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 3,093 shares in the last quarter. Hudson Bay Capital Management LP lifted its holdings in Pfizer by 1,784.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 140,165 shares of the biopharmaceutical company’s stock worth $3,571,000 after buying an additional 132,728 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its holdings in Pfizer by 11.9% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 4,521 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 482 shares in the last quarter. Severin Investments LLC boosted its position in Pfizer by 66.1% in the 3rd quarter. Severin Investments LLC now owns 37,382 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 14,872 shares during the period. Finally, Innova Wealth Partners acquired a new position in shares of Pfizer in the third quarter worth $207,000. 68.36% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.